By Nick Bolek
Marketing Specialist, Investments
How are Biotechnology Companies Raising Capital via Private Equity?
Biotechnology companies employ a range of strategies to raise private equity capital, including private placements, Regulation D SEC fundraising, crowdfunding, and partnerships with strategic and institutional investors. Private placements are one of the most common; they allow biotech firms to attract funds from accredited investors without dealing with the headache of public offerings. This option provides speed in funding while maintaining compliance with the SEC. For example, Replimune Group recently raised $100 million through a private placement, demonstrating its attractiveness to institutional investors.
Crowdfunding platforms position themselves as increasingly important tools for biotech companies looking to democratize access to investment opportunities and build community. Strategic partnerships with pharmaceutical giants provide vital funding and expertise from within the industry. In the case of Moderna, for example, its partnership with AstraZeneca was integral to its success during the COVID-19 pandemic. Institutional investors-including venture capital firms such as OrbiMed and Bain Capital-inject billions into cutting-edge innovations in the biotechnological sector.
These diverse strategies allow biotechnology firms to attract the significant capital required to move innovative research forward and create life-saving therapies, while attracting a wide range of investors.
How Are Biotechnology Companies Adhering to ESG Investment Policy Mandates?
This alignment brings biotechnology firms closer to the set investment policy mandates, which increasingly appeal to environmentally and socially responsible investors and governors of high corporate standards. Companies apply environmental concerns in resource usage by limiting greenhouse gas emissions, waste management, and utilizing energy-efficient technologies. For example, Amgen is installing energy-efficient designs in facilities and using renewable energy to decrease its carbon footprint.
Companies' social focus includes equitable access to treatments and ethical clinical trials. For example, United Therapeutics pays a minimum "living wage" for all employees and makes all employees shareholders to engender inclusiveness and social equity.
In governance, transparency and accountability are ensured. Companies like Biogen have established sophisticated ESG reporting mechanisms that highlight the progress of their sustainability and ethical business operations. Furthermore, majority voting and board declassification are being implemented by biotechnology companies to improve corporate governance. By integrating the principles of ESG into their policies, biotechnology companies meet not only regulatory requirements but also strengthen their reputation and attract socially responsible investors for long-term viability and expansion.
Companies in Biotechnology Focused on ESG Initiatives
The leading biotechnology companies are making great strides towards ESG. For example, Amgen has placed high emphasis on environmental sustainability through greener facility designs, renewable energy projects, and waste reduction. Its state-of-the-art, net-zero buildings point to great environmental responsibility.
Another leader in ESG issues, United Therapeutics focuses much attention on the themes of social equity and corporate governance. All full-time employees are given shareholder status, ensuring every employee benefits from a "living wage" policy. The company has also instituted better accountability via governance practices such as majority voting and proxy access.
GenScript Biotech is committed to green development in all its ESG strategies and integrates sustainable considerations into its operations worldwide. The company published its 2023 ESG report, where it unveiled efforts in minimizing environmental impact and building corporate social responsibility.
These three companies typify the way biotechnology companies are taking proactive steps in ESG issues and making contributions to a sustainable future and life science innovation. These efforts underscore the growing integration of ESG principles into business strategy, meeting investor and societal expectations.
Comments